Investorideas.com | big ideas for the small cap investor- One of the first online investor resources providing research tools for renewable energy, water and Homeland Security Investing Today's Investor Ideas
   research       news       insiders corner       audio       green investor       stock directories       investor sign-up       marketplace       trade       membership       Jobs     
BiotechIndustryStocks.com

Biotech Stocks and Pharma Stocks Directory at www.Biotechindustrystocks.com and www.Investorideas.com

Our biotechology stocks directory includes Stem Cell Stocks, Medical Stocks, Life Sciences, Therapeutics and Pharma Stocks . Our Directory includes publicly traded biotech stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges. Even the industry experts use our directory!

You can purchase the full Biotech Stocks Directory in PDF for just $24.95. The directory will be emailed to you in PDF format. If you decide to become a member within the first year of purchase of this directory we will reimburse your purchase cost of the individual directory.

The complete biotech directory is also accessible by login for Investor Ideas Members - Already a Member? Login Here. Not a Member? - Join Today for just $99 year

Members get login access to the Mining stocks directory, oil and gas stocks directory, Natural Gas Stocks Directory, Water Stocks Directory, Renewable energy stocks directory, Biotech Stocks Directory, Defense and Homeland Security Stocks Directory, Fuel cell stocks Directory, Environment Stocks Directory and the investor newsletter - The Insiders Corner, covering insider buying trends in small cap stocks.







3SBio Inc. (NasdaqGS:SSRX) 3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applications of the technology to cardiac and vascular regeneration. The Company currently has a cardiovascular regeneration product in Phase II development for the treatment of dilated cardiomyopathy (DCM) (called the IMPACT-DCM trial) and critical limb ischemia (called the RESTORE-CLI trial).

ABAXIS, Inc. (NasdaqGS: ABAX) Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

ABBOTT LABORATORIES (NYSE: ABT) Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

ABIOMED INC (NasdaqGM:ABMD) Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.

Abviva, Inc ( OTCPK:ABVV) is a publicly traded biomedical company established to develop and commercialize diagnostic and therapeutic products from Mammastatin, a growth-regulatory protein that inhibits breast cancer cell growth. Mammastatin is normally present in the blood serum of healthy women and absent in women with breast cancer. Abviva intends to build a fully-integrated diagnostic and therapeutic business that is sustained by future revenues from products and services the company develops; to commercialize the Mammastatin Serum Assay through our wholly owned subsidiary laboratory; and, to develop one or more breast cancer therapies through internal and external collaborative research with pharmaceutical, biotechnology and leading research institutions world wide.

Acadia Pharmaceuticals Inc. (NasdaqGM: ACAD) ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson's disease psychosis, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform.

ACAMBIS PLC ADS (OTCPK:ACAMY) Acambis is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve upon current standards of care.

Accentia Biopharmaceuticals, Inc. (OTCPK:ABPIQ) Accentia Biopharmaceuticals, Inc. is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications.

Acorda Therapeutics, Inc. (NasdaqGM:ACOR) Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

 

To view our entire Biotech/ Life Sciences Stock Directory you must be a InvestorIdeas.com Member

Click here to sign up or if you are already a member Click here to log in.

Investorideas.com memberships includes access to the Insiders Corner, providing insider trading insight and trends, the Renewable Energy Stocks Directory, Natural Gas Stocks Directory, Water Stocks Directory, Environment stocks directory, Fuel cell stocks directory, Biotech Stocks Directory and Defense Stocks Directory

Become an InvestorIdeas.com® Member for Just $99/year (starting from date of sign up)

SIGN UP NOW

Yearly Membership
US and International Canadian Residents

Already a Member? Login here with your password.

Our site does not give specific recommendations and encourages investors to complete their own due diligence. Our lists are compiled from internal and external research sources. Our lists are to be used only as a partial source of due diligence.

*Stock directory compiled and copyright property of Investorideas.com

TOP

Investor Ideas © 2000 - 2010 InvestorIdeas.com®, ECON

Today's Investor Ideas

about us | advertise | media | partners / links | affiliates | contact |
social network | jobs | disclaimer / disclosure | privacy policy |
videos | sitemap | company profile directory | login | logout |